Literature DB >> 2660982

Reversible suppression of c-myc expression in a human colon carcinoma line by the anticancer agent N-methylformamide.

D Chatterjee1, A Mendelsohn, P R Shank, T M Savarese.   

Abstract

The anticancer agent N-methylformamide (NMF), which at high concentrations (170 mM) induces cultured DLD-1 Clone A human colon carcinoma cells to increase their doubling times and lose their tumorigenicity in nude mice (Cordeiro, R.F., and Savarese, T.M. Cancer Res., 46: 1297-1305, 1986), suppresses the expression of the c-myc protooncogene in these cells in a dose- and time-dependent manner. This suppression involves an inhibition of c-myc transcription rather than an increased degradation of c-myc mRNA, and is reversed if NMF is removed from the culture medium. Expression of the glyceraldehyde 3-phosphate dehydrogenase gene, which is thought to be constitutive, is phosphate dehydrogenase gene, which is thought to be constitutive, is relatively unaffected by NMF treatment. The NMF-mediated decrease in c-myc expression may be associated with the ability of this agent to increase the doubling time of these cells, but there is no direct temporal link between the loss of c-myc expression and the NMF-induced loss of tumorigenicity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2660982

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

1.  Posttranscriptional regulation of c-myc proto-oncogene expression and growth inhibition by recombinant human interferon-beta ser17 in a human colon carcinoma cell line.

Authors:  D Chatterjee; T M Savarese
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Molecular characterization of the in vivo alkylating agent resistant murine EMT-6 mammary carcinoma tumors.

Authors:  D Chatterjee; C J Liu; D Northey; B A Teicher
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

3.  Enhancement of antitumor activity of the oxazaphosphorine cytostatic SUM-IAP by N-methylformamide.

Authors:  G Voelcker
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-03       Impact factor: 4.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.